Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SYS003
MIFTS: 49

Systolic Heart Failure

Categories: Cardiovascular diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Systolic Heart Failure

About this section

MalaCards integrated aliases for Systolic Heart Failure:

Name: Systolic Heart Failure 12 6 15 17
Heart Failure, Systolic 44 70

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:9651
ICD9CM 34 428.2
MeSH 44 D054143
SNOMED-CT 67 417996009
ICD10 32 I50.20
UMLS 70 C1135191
Sources

Summaries for Systolic Heart Failure

About this section
MalaCards based summary : Systolic Heart Failure, also known as heart failure, systolic, is related to peripartum cardiomyopathy and left bundle branch hemiblock. An important gene associated with Systolic Heart Failure is NPPB (Natriuretic Peptide B), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Colorectal Cancer Metastasis. The drugs Carvedilol and Verapamil have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and spinal cord, and related phenotypes are cardiovascular system and homeostasis/metabolism

Sources

Related Diseases for Systolic Heart Failure

About this section

Diseases related to Systolic Heart Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 524)
# Related Disease Score Top Affiliating Genes
1 peripartum cardiomyopathy 32.0 TTN ADRB1 ACE
2 left bundle branch hemiblock 31.1 NR3C2 NPPB CRP ACE
3 atrial standstill 1 31.0 TTN NPPB ADRB1 ACE
4 mitral valve insufficiency 30.8 TTN NR3C2 NPPB NPPA CRP ACE
5 tricuspid valve insufficiency 30.8 NPPB EDN1 CRP ACE
6 atrioventricular block 30.7 TTN NPPB ACE
7 myocarditis 30.6 TTN TNF NPPB IL6 ACE
8 ischemia 30.5 NPPB NOS3 EDN1 ACE
9 cardiogenic shock 30.5 TNF NPPB IL6
10 atrial fibrillation 30.5 TTN NR3C2 NPPB NPPA CRP ADRB1
11 acute myocarditis 30.5 TNF NPPB CRP ACE
12 uremia 30.4 TNF IL6 CRP ACE
13 sexual disorder 30.4 NOS3 EDN1 ACE
14 impotence 30.4 NOS3 EDN1 ACE
15 chagas disease 30.4 TNF NPPB LGALS3 IL6 ADRB1 ACE
16 coronary heart disease 1 30.4 CRP ADIPOQ ACE
17 rheumatic heart disease 30.4 TNF NPPB IL6 ACE
18 pulmonary disease, chronic obstructive 30.4 TNF NPPB MMP9 IL6 CRP ACE
19 intermediate coronary syndrome 30.3 IL6 CRP ACE
20 intermittent claudication 30.3 IL6 CRP ACE
21 coronary stenosis 30.3 NPPB IL6 CRP ACE
22 congestive heart failure 30.2 TTN TNF NR3C2 NPPB NPPA NOS3
23 decubitus ulcer 30.2 TNF MMP9 IL6 CRP
24 pericardial effusion 30.2 NPPB NPPA IL6 CRP ACE
25 gastroenteritis 30.1 TNF MMP9 IL6 CRP
26 lipid metabolism disorder 30.1 IL6 CRP ADIPOQ ACE
27 central sleep apnea 30.0 NPPB NPPA NOS3 HSPB7 CRP ACE
28 deficiency anemia 30.0 TNF NPPA IL6 CST3 CRP ACE
29 pulmonary hypertension 30.0 TNF NPPB NPPA NOS3 IL6 EDN1
30 anxiety 30.0 UCN TNF IL6 CRP ACE
31 connective tissue disease 30.0 TNF IL6 EDN1 CRP ACE
32 arteries, anomalies of 30.0 TNF NOS3 IL6 EDN1 CRP ADIPOQ
33 sleep apnea 29.9 TNF NPPB NOS3 IL6 EDN1 CRP
34 aortic valve disease 2 29.9 TTN NPPB NPPA CRP ACE
35 diastolic heart failure 29.9 TTN NPPB NPPA NOS3 MMP9 MMP2
36 heart valve disease 29.9 NR3C2 NPPB NPPA CRP ACE
37 hypertensive heart disease 29.8 NR3C2 NPPB NPPA MMP9 MMP2 CYP11B2
38 sleep disorder 29.8 TNF IL6 EDN1 CRP ADIPOQ ACE
39 leptin deficiency or dysfunction 29.8 TNF IL6 CRP ADIPOQ
40 lung disease 29.8 TNF NPPB MMP9 IL6 EDN1 CRP
41 hypothyroidism 29.7 TNF LGALS3 CST3 CRP ADIPOQ ACE
42 acute myocardial infarction 29.7 NPPB NPPA MMP9 IL6 EDN1 CST3
43 amyloidosis 29.7 TTN TNF NPPB IL6 CST3 CRP
44 mitral valve disease 29.7 NPPB NPPA NOS3 CRP ACE
45 pulmonary edema 29.6 TNF NPPB NPPA NOS3 EDN1 CRP
46 angina pectoris 29.6 NPPB NOS3 IL6 EDN1 CRP ADIPOQ
47 respiratory failure 29.5 TTN TNF NPPB NPPA IL6 EDN1
48 pheochromocytoma 29.2 TNF NPPA IL6 EDN1 CRP ADIPOQ
49 end stage renal disease 29.2 TNF NPPB NOS3 IL6 CST3 CRP
50 vascular disease 28.8 TNF NPPB NOS3 MMP9 IL6 EDN1

Graphical network of the top 20 diseases related to Systolic Heart Failure:



Diseases related to Systolic Heart Failure
Sources

Symptoms & Phenotypes for Systolic Heart Failure

About this section

MGI Mouse Phenotypes related to Systolic Heart Failure:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.43 ACE ADIPOQ ADRB1 CORIN CRP CST3
2 homeostasis/metabolism MP:0005376 10.41 ACE ADIPOQ ADRB1 CORIN CRP CST3
3 growth/size/body region MP:0005378 10.33 ACE ADIPOQ ADRB1 CORIN CYP11B2 EDN1
4 mortality/aging MP:0010768 10.25 ACE ADIPOQ ADRB1 CST3 EDN1 HSPB7
5 muscle MP:0005369 10.21 ADIPOQ ADRB1 CORIN CST3 EDN1 HSPB7
6 adipose tissue MP:0005375 10.1 ACE ADIPOQ ADRB1 CYP11B2 IL6 LGALS3
7 nervous system MP:0003631 10.07 ACE ADIPOQ CST3 CYP11B2 EDN1 IL6
8 neoplasm MP:0002006 9.92 ACE ADIPOQ CST3 IL6 LGALS3 MMP2
9 renal/urinary system MP:0005367 9.9 ACE ADIPOQ CORIN CYP11B2 EDN1 IL6
10 respiratory system MP:0005388 9.56 ADIPOQ HSPB7 IL6 LGALS3 MMP2 MMP9
11 skeleton MP:0005390 9.32 ADIPOQ ADRB1 EDN1 IL6 LGALS3 MMP2
Sources

Drugs & Therapeutics for Systolic Heart Failure

About this section

Drugs for Systolic Heart Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
2
Verapamil Approved Phase 4 52-53-9 2520
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
5
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
6
Enalaprilat Approved Phase 4 76420-72-9 6917719
7
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
8
Canagliflozin Approved Phase 4 842133-18-0
9
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
10
Bisoprolol Approved Phase 4 66722-44-9 2405
11
Hydralazine Approved Phase 4 86-54-4 3637
12
Iron Approved Phase 4 7439-89-6 23925 29936
13
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
14
Eplerenone Approved Phase 4 107724-20-9 443872 150310
15
Simendan Investigational Phase 4 131741-08-7
16
protease inhibitors Phase 4
17 HIV Protease Inhibitors Phase 4
18 calcium channel blockers Phase 4
19 Sitagliptin Phosphate Phase 4
20 Dipeptidyl-Peptidase IV Inhibitors Phase 4
21 Incretins Phase 4
22 Neurotransmitter Agents Phase 4
23 Purinergic P2Y Receptor Antagonists Phase 4
24 Prasugrel hydrochloride Phase 4 389574-19-0
25 Platelet Aggregation Inhibitors Phase 4
26 Adrenergic Antagonists Phase 4
27 Sympatholytics Phase 4
28 Adrenergic beta-1 Receptor Antagonists Phase 4
29 Angiotensin-Converting Enzyme Inhibitors Phase 4
30 Adrenergic Agents Phase 4
31 Adrenergic beta-Antagonists Phase 4
32 Antihypertensive Agents Phase 4
33 Mineralocorticoids Phase 4
34 Mineralocorticoid Receptor Antagonists Phase 4
35 Hormone Antagonists Phase 4
36 diuretics Phase 4
37 Hormones Phase 4
38 Diuretics, Potassium Sparing Phase 4
39 Phosphodiesterase Inhibitors Phase 4
40 Vasodilator Agents Phase 4
41 Sodium-Glucose Transporter 2 Inhibitors Phase 4
42 Hypoglycemic Agents Phase 4
43 Cardiotonic Agents Phase 4
44 Phosphodiesterase 3 Inhibitors Phase 4
45 Protective Agents Phase 4
46 Pharmaceutical Solutions Phase 4
47 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 4
48
Sodium citrate Approved, Investigational Phase 3 68-04-2
49
Ethanol Approved Phase 2, Phase 3 64-17-5 702
50
Ofloxacin Approved Phase 3 82419-36-1 4583

Interventional clinical trials:

(show top 50) (show all 168)
# Name Status NCT ID Phase Drugs
1 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4 Verapamil
2 Beneficial Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism Unknown status NCT02316743 Phase 4 Levothyroxine supplementation
3 A DANish Randomized, Controlled, Multicenter Study to Assess the Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality. The DANISH Study Unknown status NCT00541268 Phase 4
4 Metformin in Patients With Chronic and Acute Heart Failure: Pharmacokinetics and Polymorphisms in Genes Encoding Membrane Metformin Transporter Proteins Unknown status NCT02797340 Phase 4 Metformin
5 Efficacy and Safety of Levothyroxine (L-T4) Replacement on Exercise Capability in Chronic Systolic Heart Failure Patients With Subclinical Hypothyroidism: A 24-week, Multi-center, Open Label, Randomized, Parallel Group Trial Unknown status NCT03096613 Phase 4 Levothyroxine
6 Shensong Yangxin Capsule in the Treatment of Mild to Moderate Systolic Heart Failure Complicated With Ventricular Premature Beat: A Randomize, Double Blind, Placebo-controlled Multicenter Clinical Trial Unknown status NCT01612260 Phase 4 Shensong Yangxin capsule;placebo Capsule
7 Inspiratory Muscle Training for Dyspneic Patients With COPD-HF Overlap: a Multicenter, Randomized Controlled Trial Unknown status NCT02579200 Phase 4
8 Prophylactic Lisinopril to Prevent Anthracycline Induced Left Ventricular Systolic Dysfunction (PLAID) Study. Unknown status NCT03392740 Phase 4 Lisinopril;Placebo Oral Tablet
9 A Randomized, Double-blind, Active-controlled Study to Assess the Effect of LCZ696 Compared With Enalapril to Improve Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF). Completed NCT02768298 Phase 4 LCZ696;Enalapril;Placebo matching enalapril;Placebo matching LCZ696
10 A Randomized Active-Control Double-Blinded Study to Evaluate the Treatment of Diabetes in Patients With Systolic Heart Failure Completed NCT02920918 Phase 4 Canagliflozin;Sitagliptin
11 Platelet Reactivity With Clopidogrel Versus Prasugrel in Patients With Systolic Heart Failure Completed NCT01765400 Phase 4 Prasugrel 10 mg daily x 2 weeks;Clopidogrel 75 mg daily x 2 weeks
12 SASHFR (South Asian Systolic Heart Failure Registry) : A Multi-center, Nonrandomized, Prospective Study to Collect Data Pertaining to the Demographic and Cardiovascular Profiles, Management Strategies and Clinical Outcomes of HF Patients. Completed NCT01434615 Phase 4
13 Prospective, Open-labeled Trial in Patients With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea (PRISM) Completed NCT01074307 Phase 4 Low Dose Bisoprolol;High Dose Bisoprolol
14 Dietary Nitrate Supplementation and Cardiorespiratory Control in Chronic Heart Failure: a Randomized, Placebo-controlled Trial Completed NCT02401126 Phase 4
15 Clinical Value of Heart Rate Variability Indexes to Predict Outcomes After Exercise Training in Chronic Heart Failure Completed NCT02903225 Phase 4
16 Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality - FAIR-HF2 Recruiting NCT03036462 Phase 4 Iron;Saline
17 Effectiveness of a Repetitive Use of 24-hour Levosimendan Infusions in Patients With Severe Systolic Heart Failure in Order to Prevent Rehospitalizations Recruiting NCT03764722 Phase 4 Levosimendan
18 The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation Recruiting NCT04217135 Phase 4 evidence-based medications vs. high-dose hydralazine + evidence-based medications
19 Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin. A Ringerike Heart Failure Cohort Phase IV Study of Angiotensin Receptor Neprilysin Inhibiton Recruiting NCT03553303 Phase 4 Sacubitril / Valsartan Oral Tablet
20 Pulse Reduction On Beta-blocker and Ivabradine Therapy Recruiting NCT02973594 Phase 4 Ivabradine;Placebo
21 Cluster and Registry Trials Of the Working Group of Heart Failure in Denmark: Are SPironolactone and Eplerenone Comparable Treatments? Not yet recruiting NCT03984591 Phase 4 Eplerenone;Spironolactone
22 Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS® Not yet recruiting NCT04570865 Phase 4 Dapagliflozin
23 Levosimendan In Ambulatory Heart Failure Patients Not yet recruiting NCT04705337 Phase 4 Levosimendan
24 The Effect of Ferric Carboximaltose on Intra-myocardial Iron Load Assessed by Cardiac Magnetic Resonance in Patients With Heart Failure With Reduced Ejection Fraction (HFREF). Not yet recruiting NCT03871699 Phase 4 Ferric carboxymaltose
25 MRI Allocation of Pacing Targets in Cardiac Resynchronization Therapy Unknown status NCT01640769 Phase 3
26 Impact of Renal Artery Denervation in Patients With Chronic Heart Failure Compared With Sham Procedure Unknown status NCT01639378 Phase 3
27 Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST） Unknown status NCT02188082 Phase 2, Phase 3 IvabRadine hemisulfate Sustained-release Tablets;placebo
28 Cardiovascular Effects of Preferred Home-based Exercise Training and Extended Adherence Measures in Systolic Heart Failure - Pilot Study Unknown status NCT02051712 Phase 3
29 Phase III Study to Evaluate Efficacy and Safety of HGP1207 in Patients With Pulmonary Hypertension Associated With Systolic Heart Failure Unknown status NCT01913847 Phase 3 Sildenafil;Placebo
30 Spinal Cord Stimulation For Heart Failure As A Restorative Treatment Completed NCT01362725 Phase 2, Phase 3
31 The Effect of Short Term Oral Iron Supplementation in Systolic Heart Failure Patients Suffering From Iron Deficiency Anemia Completed NCT02998697 Phase 2, Phase 3 Ferrous Sulfate;Placebo Oral Capsule
32 Growth Hormone Treatment in Patients With Ischemic Heart Failure and Circulating Levels of NT-proBNP Completed NCT04420481 Phase 3 Somatropin;Placebo
33 Blended Collaborative Care for Heart Failure and Co-Morbid Depression Completed NCT02044211 Phase 2, Phase 3
34 The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure Completed NCT00232180 Phase 3 Eplerenone
35 Controlled Rosuvastatin Multinational Study in Heart Failure CORONA A Randomized, Double-Blind, Placebo Controlled Phase III Study With Rosuvastatin in Subjects With Chronic Symptomatic Systolic Heart Failure Completed NCT00206310 Phase 3 CRESTOR
36 A Randomized, Double-blind, Active-controlled Study to Assess the Effect of Sacubitril/Valsartan Compared With Enalapril to Improve Erectile Function in Patients With Heart Failure With Reduced Ejection Fraction and Erectile Dysfunction Recruiting NCT03917459 Phase 3 LCZ696;Enalapril matching placebo;Enalapril;LCZ696 matching placebo
37 A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure on Standard Heart Failure Therapy Recruiting NCT04468529 Phase 3 Recombinant human Neuregulin for injection;Placebo
38 Mechanisms, Safety and Efficacy of Optimising Pacemaker Heart Rate for Contractility: Effects on Walk Time, Cardiac Remodelling and Quality of Life Recruiting NCT04201015 Phase 2, Phase 3
39 A Multi-center, Randomized, Double-blined, Placebo Parallel Controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Mortality of Subjects With Chronic Systolic Heart Failure on Standard HF Therapy. Recruiting NCT03388593 Phase 3 rhNRG-1;Placebo
40 Randomized Noninferiority Study of an Antibacterial Envelope Alone Versus Envelope Plus Intraoperative Antibacterial Irrigant and Postoperative Antibiotics to Prevent Cardiac Implantable Electronic Device Infections in High-Risk Patients Recruiting NCT02809131 Phase 3 polymixin/bacitracin;cephalexin, or levofloxacin, or clindamycin;Saline
41 Investigator-initiated, Randomized, Double-blind, Controlled, Multi-center Trial of Intrvenous Iron in Patients With Cardiovascular Disease and Concomitant Iron Deficiency Recruiting NCT03991000 Phase 3 Ferric carboxymaltose;Saline
42 Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Chronic Systolic Heart Failure Terminated NCT01646515 Phase 3 Placebo;Udenafil (Zydena)
43 A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Efficacy/Safety of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure Terminated NCT01439893 Phase 3 rhNRG-1;Placebo
44 A Multi-center, Randomized, Double-blind , Placebo Parallel Controlled, Standard Therapy Based Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure Terminated NCT01214096 Phase 3 rhNRG-1;rhNRG-1;rhNRG-1;placebo
45 A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure Terminated NCT01131637 Phase 3 rhNRG-1;placebo
46 A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Efficacy/Safety of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure Terminated NCT01439789 Phase 3 rhNRG-1;Placebo
47 A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure Terminated NCT01541202 Phase 3 rhNRG-1;Placebo
48 MADIT ASIA Cardiac Resynchronization Trial (MADIT-ASIA) Terminated NCT01872234 Phase 3
49 GutHeart: Targeting Gut Microbiota to Treat Heart Failure Unknown status NCT02637167 Phase 2 Rifaximin;Saccharomyces boulardii
50 Safety and Tolerability of the Nutritional Supplement, Nicotinamide Riboside, in Systolic Heart Failure Completed NCT03423342 Phase 1, Phase 2 Placebo

Search NIH Clinical Center for Systolic Heart Failure

Cochrane evidence based reviews: heart failure, systolic

Sources

Genetic Tests for Systolic Heart Failure

About this section
Sources

Anatomical Context for Systolic Heart Failure

About this section

MalaCards organs/tissues related to Systolic Heart Failure:

40
Heart, Endothelial, Spinal Cord, Skeletal Muscle, Brain, Neutrophil, Bone
Sources

Publications for Systolic Heart Failure

About this section

Articles related to Systolic Heart Failure:

(show top 50) (show all 2421)
# Title Authors PMID Year
1
Stem cells for treatment of cardiovascular diseases: An umbrella review of randomized controlled trials. 61
33434684 2021
2
Prognostic impact of 6 min walk test distance in patients with systolic heart failure: insights from the WARCEF trial. 61
33377631 2021
3
Predictors of Hemodynamic Response to Intra-Aortic Balloon Pump Therapy in Patients With Acute Decompensated Heart Failure and Cardiogenic Shock. 61
33723089 2021
4
Cardiac Resynchronization Therapy in Patients with Heart Failure: What is New? 61
33673953 2021
5
Associations between NT-proBNP and psychosocial factors in patients with chronic systolic heart failure. 61
33601116 2021
6
Norepinephrine, plasma renin activity and cardiovascular mortality in systolic heart failure. 61
33712509 2021
7
Omecamtiv Mecarbil use in systolic heart failure- Results of the GALACTIC-HF trial. 61
33689561 2021
8
The Effects of Spironolactone and Eplerenone on Left Ventricular Function Using Echocardiography in Symptomatic Patients With New-Onset Systolic Heart Failure: A Comparative Randomised Controlled Trial. 61
33744193 2021
9
Novel Estimation of Left Ventricular Filling Pressure Using 3-D Speckle-Tracking Echocardiography: Assessment in a Decompensated Systolic Heart Failure Model. 61
33771416 2021
10
Time overlap of mitral and aortic regurgitations in a patient with systolic heart failure. 61
33599456 2021
11
Neurohormones and death in systolic heart failure: keep your friends close, but your enemies closer. 61
33737454 2021
12
Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failure. 61
32598074 2021
13
Clinical and hemodynamic effects of oral sildenafil on biventricular function on patients with left ventricular systolic dysfunction. 61
33764636 2021
14
Identifying At-Risk Patients for Sustained Atrial High-Rate Episodes Using the C2HEST Score: The West Birmingham Atrial Fibrillation Project. 61
33666093 2021
15
Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23. 61
33677556 2021
16
Competing risks in patients with primary prevention implantable cardioverter-defibrillators: Global Electrical Heterogeneity and Clinical Outcomes (GEHCO) study. 61
33684549 2021
17
Ambulatory advanced heart failure patients: timing of mechanical circulatory support - delaying the inevitable? 61
33395078 2021
18
Primary Prevention ICD Therapy in Heart Failure with Recovered Ejection Fraction. 61
33636331 2021
19
Sudden cardiac death after implantation of a cardiac resynchronization therapy pacemaker: a case report illustrating that not always less is more. 61
33738405 2021
20
Morphologies and prognostic significance of left ventricular volume/time curves with cardiac magnetic resonance in patients with non-ischaemic heart failure and left bundle branch block. 61
33635416 2021
21
Tuberculosis Presenting With Acute Myocarditis and Systolic Heart Failure. 61
33728179 2021
22
Long-term outcomes of index cryoballoon ablation or point-by-point radiofrequency ablation in patients with atrial fibrillation and systolic heart failure. 61
33527562 2021
23
Association of Ischemic Evaluation and Clinical Outcomes Among Patients Admitted With New-Onset Heart Failure. 61
33586468 2021
24
Intravenous Infusion of the β3-Adrenergic Receptor Antagonist APD418 Improves Left Ventricular Systolic Function in Dogs With Systolic Heart Failure. 61
33352205 2021
25
Response to letter to the editor entitled "Association between left atrial sphericity index and clinical outcomes in patients with systolic heart failure". 61
33555050 2021
26
Prognostic value of estimated plasma volume in patients with chronic systolic heart failure. 61
33443059 2021
27
Epidemiology of acutely decompensated systolic heart failure over the 2003-2013 decade in Douala General Hospital, Cameroon. 61
33225620 2021
28
Semi-quantification of renal perfusion using 99mTc-DTPA in systolic heart failure: a feasibility study. 61
33386522 2021
29
No impact of mineralocorticoid receptor antagonists on long-term recurrences of ventricular tachyarrhythmias. 61
33314234 2021
30
[Evidence based guideline for cardiac rehabilitation in German speaking countries of Europe]. 61
33513651 2021
31
Association between left atrial sphericity index and clinical outcomes in patients with systolic heart failure. 61
33537995 2021
32
Trajectories of Left Ventricular Ejection Fraction After Acute Decompensation for Systolic Heart Failure: Concomitant Echocardiographic and Systemic Changes, Predictors, and Impact on Clinical Outcomes. 61
33496189 2021
33
Catabolic/Anabolic Imbalance Is Accompanied by Changes of Left Ventricular Steroid Nuclear Receptor Expression in Tachycardia-Induced Systolic Heart Failure in Male Pigs. 61
33450412 2021
34
Stimulation of Contractility in Systolic Heart Failure. 61
33497552 2021
35
Electrocardiogram lead selection for intelligent screening of patients with systolic heart failure. 61
33479367 2021
36
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. 61
33185990 2021
37
B-type natriuretic peptide (BNP) predicts 90-day mortality and need for paracentesis in cirrhotic patients without systolic heart failure. 61
33462246 2021
38
Performance of Atrial Fibrillation Risk Prediction Models in Over 4 Million Individuals. 61
33295794 2021
39
Cardiac Myosin Activation for the Treatment of Systolic Heart Failure. 61
33165138 2021
40
Dealing with RV-oversensing; separate sensitivity settings for brady and tachy sensing. 61
33238071 2021
41
Partial anomalous pulmonary venous return after orthotopic heart transplantation case report. 61
33407125 2021
42
Left atrial appendage morphology predicts the formation of left atrial appendage thrombus. 61
33512055 2021
43
Transcatheter reshaping of the mitral annulus in patients with functional mitral regurgitation: one-year outcomes of the MAVERIC trial. 61
32718911 2021
44
Importance of Systematic Right Ventricular Assessment in Cardiac Resynchronization Therapy Candidates: A Machine Learning Approach. 61
33422667 2021
45
Transcatheter Edge-to-Edge Repair With MitraClip in Systolic Heart Failure With Ischemic Versus Nonischemic Cardiomyopathy. 61
33303125 2020
46
Predicting ventricular tachyarrhythmia in patients with systolic heart failure based on texture features of the gray zone from contrast-enhanced magnetic resonance imaging. 61
32675026 2020
47
Catheter Ablation Versus Medication in Atrial Fibrillation and Systolic Dysfunction: Late Outcomes of CAMERA-MRI Study. 61
33334453 2020
48
Exercise dynamics of cardiac biomarkers and hemoconcentration in patients with chronic systolic heart failure. 61
32687881 2020
49
Modeling of Virtual Mechanical Circulatory Hemodynamics for Biventricular Heart Failure Support. 61
33215365 2020
50
Update on COVID-19 Myocarditis. 61
33317101 2020
Sources

Variations for Systolic Heart Failure

About this section

ClinVar genetic disease variations for Systolic Heart Failure:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TTN NM_001267550.2(TTN):c.5668C>T (p.Arg1890Cys) SNV Likely benign 47210 rs146496197 GRCh37: 2:179640923-179640923
GRCh38: 2:178776196-178776196
2 DSP NM_004415.4(DSP):c.8300C>A (p.Thr2767Asn) SNV Benign 44963 rs34884895 GRCh37: 6:7585795-7585795
GRCh38: 6:7585562-7585562
3 DTNA NM_032975.4(DTNA):c.1186C>A (p.Pro396Thr) SNV Benign 46411 rs77320474 GRCh37: 18:32431798-32431798
GRCh38: 18:34851834-34851834
4 ANKRD1 NM_014391.3(ANKRD1):c.827C>T (p.Ala276Val) SNV Benign 45639 rs35550482 GRCh37: 10:92675322-92675322
GRCh38: 10:90915565-90915565
5 DSG2 NM_001943.5(DSG2):c.1543G>A (p.Val515Ile) SNV Benign 36010 rs2230235 GRCh37: 18:29116284-29116284
GRCh38: 18:31536321-31536321
Sources

Expression for Systolic Heart Failure

About this section
Search GEO for disease gene expression data for Systolic Heart Failure.
Sources

Pathways for Systolic Heart Failure

About this section

Pathways related to Systolic Heart Failure according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 65
Show member pathways
 13.28 TNF NPPB NPPA NOS3 MMP9 MMP2
2
Colorectal Cancer Metastasis 63
12.14 TNF MMP9 MMP2 IL6
3
MicroRNAs in cardiomyocyte hypertrophy 1
Show member pathways
 12.11 TNF NPPB NPPA EDN1
4
Spinal Cord Injury 1
11.96 TNF MMP9 LGALS3 IL6
5
Fluid shear stress and atherosclerosis 36
11.94 TNF NOS3 MMP9 MMP2 EDN1
6
Interleukin-4 and 13 signaling 65
11.93 TNF MMP9 MMP2 IL6
7
TNF signaling pathway 36
11.92 TNF MMP9 IL6 EDN1
8
HIF-1 signaling pathway 36
11.9 NPPA NOS3 IL6 EDN1
9
Dilated cardiomyopathy 36
Show member pathways
 11.9 TTN TNF IL6 EDN1 ADRB1 ACE
10
Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics 60
Show member pathways
 11.71 NR3C2 NOS3 CYP11B2 ACE
11
AGE-RAGE signaling pathway in diabetic complications 36
11.65 TNF NOS3 MMP2 IL6 EDN1
12
LPA receptor mediated events 1
11.62 MMP9 MMP2 IL6
13
Renin secretion 36
11.62 NPPA EDN1 ADRB1 ACE
14
AGE/RAGE pathway 1
11.58 NOS3 MMP9 MMP2 LGALS3
15
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.53 TNF MMP9 MMP2 IL6
16
Photodynamic therapy-induced AP-1 survival signaling. 1
11.51 TNF MMP2 IL6
17
African trypanosomiasis 36
11.35 TNF NPPA IL6
18
amb2 Integrin signaling 1
11.35 TNF MMP9 MMP2 IL6
19
Endothelin Pathways 1
11.31 NOS3 EDN1 ADRB1
20
A-beta Pathways: Uptake and Degradation 64
11.27 MMP9 MMP2 ACE
21
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.15 NOS3 MMP9 MMP2 IL6
22
Plasma membrane estrogen receptor signaling 1
11.14 NOS3 MMP9 MMP2
23
Transcription factor regulation in adipogenesis 1
11.05 TNF IL6 ADIPOQ
24
Overview of nanoparticle effects 1
10.98 TNF IL6 CRP
25
Lung fibrosis 1
10.82 TNF MMP9 MMP2 IL6 EDN1
26
A-beta Pathways: Plaque Formation and APP Metabolism 64
10.62 MMP9 MMP2 CST3 ACE
Sources

GO Terms for Systolic Heart Failure

About this section

Cellular components related to Systolic Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 TNF NPPB NPPA MMP9 MMP2 LGALS3
2 collagen-containing extracellular matrix GO:0062023 9.55 NPPA MMP9 MMP2 LGALS3 ADIPOQ
3 extracellular region GO:0005576 9.5 UCN TTN TNF NPPB NPPA MMP9

Biological processes related to Systolic Heart Failure according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.93 UCN TTN TNF NOS3 IL6 CRP
2 cellular protein metabolic process GO:0044267 9.89 NPPA MMP2 IL6 CST3
3 positive regulation of protein phosphorylation GO:0001934 9.87 UCN TNF MMP9 ADIPOQ
4 response to hypoxia GO:0001666 9.8 NPPA MMP2 EDN1 ADIPOQ
5 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.76 TNF NR3C2 EDN1
6 positive regulation of interleukin-8 production GO:0032757 9.72 TNF IL6 ADIPOQ
7 negative regulation of fat cell differentiation GO:0045599 9.69 TNF IL6 ADIPOQ
8 response to glucocorticoid GO:0051384 9.67 UCN TNF IL6 ADIPOQ
9 response to activity GO:0014823 9.65 IL6 EDN1 ADIPOQ
10 regulation of neuroinflammatory response GO:0150077 9.63 MMP9 IL6
11 cellular response to UV-A GO:0071492 9.62 MMP9 MMP2
12 cGMP biosynthetic process GO:0006182 9.62 NPPB NPPA
13 positive regulation of smooth muscle cell proliferation GO:0048661 9.62 TNF MMP2 IL6 EDN1
14 positive regulation of cardiac muscle contraction GO:0060452 9.61 UCN NPPA
15 receptor guanylyl cyclase signaling pathway GO:0007168 9.61 NPPB NPPA
16 negative regulation of blood pressure GO:0045776 9.61 UCN NOS3 ADIPOQ
17 neutrophil mediated immunity GO:0002446 9.6 IL6 ACE
18 body fluid secretion GO:0007589 9.58 NPPB EDN1
19 regulation of blood vessel diameter GO:0097746 9.58 NPPB NOS3 ACE
20 vascular endothelial growth factor production GO:0010573 9.56 TNF IL6
21 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.56 TNF MMP9 MMP2 EDN1
22 positive regulation of mononuclear cell migration GO:0071677 9.54 TNF LGALS3
23 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.52 NOS3 EDN1
24 negative regulation of hormone secretion GO:0046888 9.33 UCN EDN1 ADIPOQ
25 negative regulation of lipid storage GO:0010888 9.13 TNF IL6 CRP
26 regulation of blood pressure GO:0008217 9.1 NPPB NPPA NOS3 EDN1 CORIN ACE

Molecular functions related to Systolic Heart Failure according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.56 TNF IL6 EDN1 ADIPOQ
2 endopeptidase activity GO:0004175 9.26 MMP9 MMP2 CORIN ACE
3 hormone receptor binding GO:0051427 9.16 NPPB NPPA
4 hormone activity GO:0005179 9.02 UCN NPPB NPPA EDN1 ADIPOQ
Sources

Sources for Systolic Heart Failure

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....